Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 27;19(8):52.
doi: 10.1007/s11892-019-1175-9.

Precision Medicine: Long-Term Treatment With Sulfonylureas in Patients With Neonatal Diabetes Due to KCNJ11 Mutations

Affiliations
Free PMC article
Review

Precision Medicine: Long-Term Treatment With Sulfonylureas in Patients With Neonatal Diabetes Due to KCNJ11 Mutations

Lisa R Letourneau et al. Curr Diab Rep. .
Free PMC article

Abstract

Purpose of review: The goal of this review is to provide updates on the safety and efficacy of long-term sulfonylurea use in patients with KCNJ11-related diabetes. Publications from 2004 to the present were reviewed with an emphasis on literature since 2014.

Recent findings: Sulfonylureas, often taken at high doses, have now been utilized effectively in KCNJ11 patients for over 10 years. Mild-moderate hypoglycemia can occur, but in two studies with a combined 975 patient-years on sulfonylureas, no severe hypoglycemic events were reported. Improvements in neurodevelopment and motor function after transition to sulfonylureas continue to be described. Sulfonylureas continue to be an effective, sustainable, and safe treatment for KCNJ11-related diabetes. Ongoing follow-up of patients in research registries will allow for deeper understanding of the facilitators and barriers to long-term sustainability. Further understanding of the effect of sulfonylurea on long-term neurodevelopmental outcomes, and the potential for adjunctive therapies, is needed.

Keywords: DEND syndrome; Glyburide; KCNJ11; Monogenic diabetes; Neonatal diabetes; Sulfonylurea.

Conflict of interest statement

Conflict of Interest The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

Publication types

LinkOut - more resources

Feedback